



ASX Release
12 March 2026

Acrux receives \$0.55 million advance on FY26 R&D Tax Incentive

Melbourne, Australia; Acrux Limited (ASX:ACR) is pleased to announce it has received a second advance in relation to its FY26 R&D Tax Incentive (RDTI) from Radium Capital. This advance relates to the period 1 October 2025 to 28 February 2026. It totals \$0.55 million, broadly representing 80% of the estimated RDTI for the four month period.

Following the US Food and Drug Administration's (FDA) confirmation of Acrux's Hormone Replacement Therapy (HRT) regulatory pathway, funds will be used to support the progression of development products and management of working capital.

Acrux uses this short term funding facility to give early access to the RDTI rebate, closer to the period of expenditure. The terms of this second advance for FY26 are unchanged to the first advance as announced on 13 November 2025.

Authorised for release by the Board of Acrux Limited.

About Acrux

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. For further information on Acrux, visit: www.acrux.com.au

For more information, please contact:

John Warmbrunn
CEO & Managing Director
Acrux Limited

P: + 61 3 8379 0100

E: john.warmbrunn@acrux.com.au

For personal use only